Bionano Genomics (BNGO) vs Daxor (DXR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Daxor (DXR) has outperformed Bionano Genomics (BNGO) over the past year, losing 18.2% versus a loss of 32.6%. Over five years, DXR leads with a -7.5% price change compared with -100.0% for BNGO. Daxor is the larger company by market cap ($60.8 million vs $16.9 million), about 3.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNGO | DXR |
|---|---|---|
| Share price | $1.44 | $10.41 |
| Market cap | $16.90M | $60.78M |
| 1-day change | -1.71% | -0.48% |
| YTD return | -6.21% | -29.42% |
| 1-year return | -32.63% | -18.22% |
| 5-year return | -99.95% | -7.47% |
| P/E ratio (TTM) | — | 9.46 |
| EPS (TTM) | $-2.98 | $1.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.23 | $14.76 |
| 52-week low | $1.00 | $8.56 |
| Distance from 52-week high | -35.65% | -29.47% |
| Analyst consensus | none | none |
| Avg. price target upside | +248.43% | +92.12% |
| Average volume | 921.59K | 17.27K |
| Shares outstanding | 11.78M | 5.84M |
| Employees | 95 | — |
| Sector | Industrials | Health Care |
| Industry | Biotechnology: Laboratory Analytical Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Daxor is about 3.6 times larger than Bionano Genomics by market value ($60.78M vs $16.90M).
- DXR has outperformed BNGO by 14.4 percentage points over the past year.
- The two companies sit in different sectors: Bionano Genomics in Industrials and Daxor in Health Care.
About Bionano Genomics
BNGO stock →Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants.
Industrials · Biotechnology: Laboratory Analytical Instruments · 95 employees
About Daxor
DXR stock →Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit.
Health Care · Medical/Dental Instruments
BNGO vs DXR FAQ
Which is bigger, Bionano Genomics or Daxor?
Daxor (DXR) is larger, with a market capitalization of $60.78M compared with $16.90M for Bionano Genomics (BNGO).
Which stock has performed better over the past year, BNGO or DXR?
DXR returned -18.22% over the past 12 months, compared with -32.63% for BNGO (price return, excluding dividends). Past performance does not predict future results.
Are Bionano Genomics and Daxor in the same industry?
No. Bionano Genomics is in the Industrials sector, while Daxor is in Health Care.